520A.T
J-Pharma Co.,Ltd.
グロース · 医薬品 · 医薬品 · JP
JPY 349.00
−10.74%Sep 2, 2026, 01:01 UTC
J-Pharma announced a transition to an executive officer system to strengthen management and business execution, with Shinya Hirata newly appointed as executive officer in charge of clinical development and regulatory affairs.
Aug 17, 2026, 03:35 UTC
The USFDA completed an inspection of Aurolife Pharma's Raleigh Plant in North Carolina, USA, from 24 March 2025 to 10 April 2025, issued a Form 483 with 11 observations, and subsequently closed the inspection with a Voluntary Action Indicated (VAI) classification.
Source:Aug 12, 2026, 07:00 UTC
J-Pharma Co., Ltd. announced its financial results for the first quarter of fiscal year ending March 2027 (April-June 2026), reporting an ordinary loss of 5.6 billion yen.
Source:Aug 5, 2026, 23:59 UTC
Nxera Pharma is expected to announce its quarterly earnings on Friday, August 7th.
Source: